North America Sleep Disorder Treatment Market is expected to grow with the CAGR of 8.6% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/north-america-sleep-disorder-treatment-market
North America sleep disorder treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in North America sleep disorder treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.
For instance,
- In January 2018, Aurobindo Pharma USA received the U.S. FDA approval for its generic drug named Armodafinil Tablets, 50 mg, 150 mg, and 250 mg for treating sleep apnea and narcolepsy. This new drug approved by the company has strengthened its sleep disorder portfolio leading to increased sales and demand in future
Jazz Pharmaceuticals plc is the dominating player in North America sleep disorder treatment market. The other key players existing in the market includes Pfizer Inc., Viatris Inc., Arbor Pharmaceuticals, Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), sanofi-aventis U.S. LLC (a subsidiary of Sanofi), Hikma Pharmaceuticals PLC , Amneal Pharmaceuticals LLC., Lupin Pharmaceuticals, Inc. (a subsidiary of Lupin), Taj Pharmaceuticals Limited, Eli Lilly and Company, Mallinckrodt, Alembic Pharmaceuticals Limited, Apotex Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Taro Pharmaceutical Industries Ltd., Koninklijke Philips N.V., DeVilbiss Healthcare LLC, ResMed , SomnoMed, Oventus and BMC Medical Co.
Jazz Pharmaceuticals plc:
Jazz Pharmaceuticals plc was founded in 2003, headquartered in Dublin, Ireland. The company is engaged in the developing life-changing medicines for people with serious or rare diseases having limited or no treatment options in order to make them live a better life. The company is providing products under sleep therapeutic area and hematology/oncology therapeutic area out of which sleep therapeutic area is the market focused category.
- In September 2020, Jazz Pharmaceuticals plc announced the collaboration with American Heart Association's sleep health educational content in order to strengthen its sleep heath therapeutic area. This new collaboration done by the company has increased its credibility in the market.
The company has wide presence across Asia-Pacific, Europe, Middle East and Africa, North America and South America. The company has various subsidiaries such as Jazz Pharmaceuticals Ireland Limited (Ireland), Gentium S.R.L. (Italy), Jazz Pharmaceuticals France SAS (France), Celator Pharmaceuticals, Inc. (U.S.) and Jazz Capital Limited (Ireland) among others.
Eli Lilly and Company:
Eli Lilly and Company was founded in 1876, headquartered in Indiana, U.S. The company is engaged in production and trading of high-quality medicines for which comes under the human pharmaceutical products. The product categories of the company include historic medicines, current medicines among which historic medicines are the market focused category.
For instance-
- In April 2007, Eli Lilly and Company announced Hypnion, Inc., a private company specialized in sleep disorder research. This acquisition done by the company has strengthened its neuroscience business segment leading to increased revenue in the future
The company has a wide presence across North America, Asia-Pacific, South America, Europe, Latin America. The company has various subsidiary companies such as Alnara Pharmaceuticals, Inc. (U.S.), AME Torreview LLC (U.S.), Andean Technical Operations Center (Peru), Dista-Produtos Quimicos & Farmaceuticos, LDA (Portugal) and E L Management LLC ( U.S.) among others. The company has initiated many strategic initiatives to expand its market.
Viatris Inc.
Viatris Inc. headquartered in Pennsylvania, U.S. was founded in 1961. The company is mainly working in the healthcare domain with the production of drugs including prescription generic, branded generic, brand name and biosimilar drugs as well as over-the-counter remedies. The product categories of the company include therapeutic areas, brands, biosimilar generics, over counter and API out of which generics is the market-focused category.
- In November 2019, Mylan N.V. announced the combination of the company with Upjohn, a division of Pfizer, the new company formed will be named as Viatris. The merger of both the company to develop a combined firm has expanded the company’s product portfolio leading to increased demand for its product in the market
The company has a wide presence across North America, Europe, South America, Asia-Pacific, Middle East and Africa.
